TITLE

FDA panel nixes interferon indication

AUTHOR(S)
Reiman, Patty
PUB. DATE
January 2000
SOURCE
Dermatology Times;Jan2000, Vol. 21 Issue 1, p13
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on the United States Food and Drug Administration's Oncologic Drugs Advisory Committee's rejection of interferon type Roferon-A for treatment of surgically resected malignant melanoma. Absence of survival advantage in the study; Exclusion of some patients from the trial.
ACCESSION #
2745675

 

Related Articles

  • Avonex approved for people at "high risk" of MS.  // Inside MS;Jul-Sep2003, Vol. 21 Issue 3, p28 

    Reports that the U.S. Food and Drug Administration (FDA) has approved the labeling of Avonex or interferon beta-1a to cover people considered to be at high risk for developing clinically definite multiple sclerosis (MS). Role played by a study on the effectiveness of Avonex in delaying or...

  • Betaseron approved for secondary-progressive MS.  // Inside MS;Jul-Sep2003, Vol. 21 Issue 3, p29 

    Announces that the U.S. Food and Drug Administration (FDA) has approved revised labeling of Betaseron or interferon beta-1b to extend its use to treat people with relapsing forms of multiple sclerosis (MS). Influence of the clinical trials of Betaseron in people with secondary-progressive MS on...

  • Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma. Raedler, Lisa A. // Journal of Hematology Oncology Pharmacy;2016Specialissue, Vol. 6, p54 

    The article provides information approval of Imlygic (Talimogene Laherparepvec), an oncolytic viral therapy for treatment of Patients with Recurrent Melanoma, by U.S. Food and Drug Administration (FDA).

  • Current management and novel agents for malignant melanoma. Lee, Byung; Mukhi, Nikhil; Liu, Delong // Journal of Hematology & Oncology;2012, Vol. 5 Issue 1, p1 

    Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents approved for treatment of melanoma by Food and Drug Administration. These include pegylated interferon alpha- 2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with...

  • FDA panel recommends approval of Schering-Plough's melanoma drug.  // PharmaWatch: Cancer;Nov2009, Vol. 8 Issue 11, p20 

    The article reports on the announcement by U.S.-based healthcare company Schering-Plough Corp. that the Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee recommends approval of its Pegintron, a melanoma drug. It is noted that Pegintron is a form of protein interferon...

  • Nocturnal leg cramp OTCs banned by FDA.  // Drug Topics;9/5/94, Vol. 138 Issue 17, p8 

    Reports that the Food & Drug Administration (FDA) has banned the sale of over-the-counter products for the treatment and/or prevention of nocturnal leg muscle cramps, effective February 22, 1995.

  • The other drug war. Postrel, Virginia I. // Reason;Nov96, Vol. 28 Issue 6, p4 

    Editorial. Comments on the US Food and Drug Administration's (FDA) drug approval policy. Speed of the FDA's drug review and approval procedures; Impact on Americans' ability to benefit from drugs' benefits.

  • FDA wants more Rx safety data.  // Drug Topics;11/7/94, Vol. 138 Issue 21, p7 

    Reports on the requirement for drug manufacturers to submit safety reports to the Food and Drug Administration.

  • Blockbuster generics hit market.  // Drug Topics;1/23/95, Vol. 139 Issue 2, p7 

    Reports on the US Food & Drug Administration's (FDA) approval of 219 generic drug and antibiotic applications in 1994. Approved medicine with branded sales greater than $50 million.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics